欧美精品一区在线_91精品国产综合久久蜜桃_国产AV网址大全_久久久国产99久久国产久_91精品国产综合久久小仙女

[China Pharmaceutical Network Industry News] In recent years, Shenzhen has attached great importance to the cultivation and development of biological and life health industries. In the process of industrial transformation, Pingshan District has seized the opportunity, and the biomedical industry has become one of the pillar industries of Pingshan. In addition, at present, the Shenzhen Biomedical Innovation Industrial Park has also introduced two common service platforms for the biological industry-Guangdong Medical Device Quality Supervision and Inspection Institute and the China-Israel Science and Technology Innovation Service Center to promote the healthy development of the biomedical industry.

(Shenzhen continues to explore opportunities and paths for the international development of biomedicine)

On September 22, the "Shenzhen·Pingshan International Biomedical Industry Innovation and Development Summit" co-sponsored by the Shenzhen Municipal Commission for the Promotion of International Trade and the Pingshan District Government was held in Pingshan District, Shenzhen. Seven academicians from home and abroad, as well as well-known experts and scholars, will visit the scene to discuss the development opportunities and paths of Shenzhen's biomedicine investment under the background of the Guangdong-Hong Kong-Macao Bay Area.

In recent years, Shenzhen has attached great importance to the cultivation and development of biological and life health industries. In the process of industrial transformation, Pingshan District has seized the opportunity. The biomedical industry has become one of Pingshan’s pillar industries, and hundreds of billions will be formed during the "13th Five-Year Plan" period. Level of output value scale.

The arrival of the Shenzhen Pingshan International Biomedical Industry Innovation and Development Summit will play an important role as a platform for Pingshan and even Shenzhen to integrate high-end resources in the entire industry chain of the biological field and promote domestic and foreign biotechnology exchanges and cooperation.

Cross-border integration of biomedical engineering

Realize the international development of the industry

The construction of the Guangdong-Hong Kong-Macao Greater Bay Area puts forward higher requirements for industrial development. It is not only necessary to enhance the ability to allocate resources and the leading function of the industrial chain, but also to further enhance the ability to radiate the economy to the outside.

The Shenzhen Pingshan International Biomedical Industry Innovation and Development Summit was held to gather the cutting-edge wisdom of experts and scholars in the global biomedicine field and elites from all walks of life to discuss in-depth innovative ideas in the development strategy of the Guangdong-Hong Kong-Macao Greater Bay Area and accelerate the crossover of biomedical engineering Integration and advanced layout will realize the large-scale, agglomeration and international development of the biomedical industry.

Including American Academy of Engineering, School of Medicine, Academician of the Third World Academy of Sciences, Foreign Academician of Chinese Academy of Engineering Cato T. Laurencin, Ding Jian, Academician of Chinese Academy of Engineering, Yan Deyue, Academician of Chinese Academy of Sciences, Zhang Xuemin, Academician of Chinese Academy of Sciences, Sun Yongkui, Academician of American Academy of Engineering , Zhao Xiaobin, academician of the Royal Society of Chemistry, Han Zhongchao, academician of the French National Academy of Technology, a total of 7 academicians and a group of famous experts and scholars will discuss the development of the biomedical industry. In addition, there are 8 teams participating in the summit roadshow, which will bring the latest research results in biomedicine such as the development of next-generation peptide antibiotics, the precise detection technology of tumors based on exosomes, the research and development and industrialization of articular cartilage regeneration.

Prior to this, the Shenzhen Municipal Government has successfully hosted the 6th Biological Exhibition and the 4th "Shenzhen International BT Leaders Summit". Every year, the exhibition attracts hundreds of well-known domestic and foreign companies, research institutions, and experts and scholars from all over the world. Biological resources have played an important role in promoting exchanges and cooperation in biotechnology.

"Thirteenth Five-Year" period biological industry

base will reach 100 billion output value scale

In recent years, Shenzhen has attached great importance to the cultivation and development of biological and life health industries. In the process of industrial transformation, Pingshan District has seized the opportunity, and the biomedical industry has become one of Pingshan’s pillar industries.

The Shenzhen National Bio-industry Base in Pingshan District is one of the first batch of 3 bio-industry bases in the country approved by the National Development and Reform Commission in 2005, covering an area of ??3.29 square kilometers. Over the years, the base has insisted on taking independent innovation as the leading strategy for industrial development, and has introduced more than 70 talent teams at all levels, including academician teams, "Thousand Talents Program" teams, etc., to focus on cultivating technologically-leading market entities.

The national bio-industry base adopts the "triple jump" model of incubation, acceleration, and land supply, forming a whole industry chain support system from business incubation to project research and development, from achievement transformation to market expansion, and from financial support to listing and financing.

As the iconic supporting facility of Shenzhen's national bio-industry base, Shenzhen Biomedical Innovation Industrial Park is a large-scale industrial carrier constructed to gather high-quality resources in the biomedical field and promote the rapid expansion of high-growth small and medium-sized enterprises. It is also the current city of Shenzhen. The few specialized bio-industrial parks that meet GMP construction standards were constructed by Shenzhen Investment Holdings Co., Ltd. with an investment of 700 million yuan, covering an area of ??123,400 square meters, with a total construction area of ??220,000 square meters, and a total of 10 buildings.

At present, the Shenzhen Biomedical Innovation Industrial Park has introduced two common service platforms for the biological industry-Guangdong Medical Device Quality Supervision and Inspection Institute and the China-Israel Science and Technology Innovation Service Center. The Guangdong Medical Device Quality Supervision and Inspection Institute is a public participation management institution directly under the Guangdong Food and Drug Administration. It is the only national medical device quality inspection institute designated by the State Food and Drug Administration in South China. It is expected to be completed in the first quarter of 2018. Construction. The China-Israel Science and Technology Innovation Service Center, operated by Israel’s outstanding technology service organizations, will be built as a demonstration platform for the introduction of Israeli high-end industrial projects, technology transfer and technological achievement transformation in the Pearl River Delta region and even the whole country. It will introduce outstanding Israeli industry service companies, Technological service and achievement transformation companies and professional incubator operators promote the achievement transformation of high-quality biomedical projects in Pingshan.

Currently, Pingshan’s biomedicine industry has gathered more than 120 biomedicine and medical device companies and service organizations. Among them, there are more than 50 biopharmaceutical companies, including Microchip Biotechnology, which is engaged in the research and development of a class of innovative drugs, Sanofi, a Fortune 500 company, and Heshuntang, which is engaged in the research and development of fine Chinese medicine. There are more than 40 medical device companies, including Libang Precision Instrument Co., Ltd., which is engaged in the research and development of multi-parameter monitoring and in vitro diagnostic equipment, and a new industry biological company, which specializes in the research and development of clinical inspection and analysis instruments, and so on.

During the "13th Five-Year Plan" period, the bio-industry base will introduce a number of major projects with a total investment of over 15 billion yuan, forming an eastern bio-industry cluster with an output value of 100 billion yuan.

link 7 academicians attended the meeting

American Academy of Engineering, School of Medicine, Academician of the Third World Academy of Sciences, Foreign Academician of Chinese Academy of Engineering

Cato T. Laurencin

World-renowned biomaterial science and engineering expert, orthopedic surgeon, and founder of regeneration engineering. Its engineering and scientific achievements have been outstanding, and have won the President Clinton Award (1995), the Obama Presidential Award (2010), and the Millennium Foundation "Science and Technology Leadership Award" (2001). He created the first artificial ligament and was selected as "Scientific American" "Global Technology Leaders 50" (2007).

Ding Jian, Academician of Chinese Academy of Engineering

is currently the dean of the School of Pharmacy, University of Chinese Academy of Sciences, and the director of the Academic Committee of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Its focus is on the discovery of new targeted anti-tumor molecules, the discovery of new mechanisms of action, and the confirmation of new biomarkers, which are the systematic research goals, and important progress has been made in the research of molecularly targeted anti-tumor drugs.

Yan Deyue, Academician of the Chinese Academy of Sciences

Macromolecular chemist, long-term research on the kinetic theory of non-steady state polymerization, polymer conformation statistics, molecular design of hyperbranched polymers and supramolecular self-assembly of irregular polymers, and discovered macro-scale supramolecules in the laboratory Self-assembly phenomenon.

Academician of the Chinese Academy of Sciences Zhang Xuemin

He has successively served as chief scientist of major national scientific research projects, academic leader of the "Tumor Biology" innovative research group of the National Foundation of China, member of the Special Committee of the Food Safety Committee of the State Council, and has long been engaged in research on the relationship between inflammation and tumors. The main research results have been successively in Published in international academic journals such as NatureImmunology and NatureMedicine. He has won the "National Natural Science Award", "Tan Jiazhen Life Science Achievement Award" and so on.

Sun Yongkui, Academician of the American Academy of Engineering

Ph.D. in Chemistry from California Institute of Technology. He has won the 2005 British Association of Chemical Engineers AstraZeneca Green Chemistry and Engineering Excellence Award, and the 2005 and 2006 US Presidential Green Chemistry Challenge Awards (US Environmental Protection Agency, Washington).

Academician of the Royal Society of Chemistry Zhao Xiaobin

Currently a member of the Royal Society of Chemistry, a chartered chemist, a member of the Society of Materials, Minerals and Mining, a member of the British Institute of Materials, a member of the American Society for Biomaterials, has published 45 scientific papers and works, and holds a number of international patents. Its main research direction is the surface body repair technology of biological materials with biocompatibility.

Han Zhongchao, Academician of the French National Academy of Technology

is mainly engaged in the research and development of blood vascular cell molecular biology and biotechnology, and has achieved many international leading academic achievements in the research of stem cells, megakaryocytes and platelets, angiogenesis and its control, chemokines, etc.

Original title: Exploring opportunities and paths for the international development of biomedicine

teaches you the whole process of using APP (Pharmaceutical Link) to seize business opportunities

(Source: NetEase)